Isolation and Characterization of Chemo-Resistant Stem Cells from a Mouse Model of Hereditary Non-Polyposis Colon Cancer

References

• Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colon cancer. Nat Rev Cancer. 2001;1:55–67. doi:10.1038/35094067
   PubMed Web of Science ®Google Scholar
• Lynch HT, de la Chepelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–932. doi:10.1056/NEJMra012242
   PubMed Web of Science ®Google Scholar
• Rustgi A. The genetics of hereditary colon cancer. Genes Dev. 2007;21:2525–2538. doi:10.1101/gad.1593107
   PubMed Web of Science ®Google Scholar
• Rajgopalan H, Novak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003;3:695–701. doi:10.1038/nrc1165
   Web of Science ®Google Scholar
• Fodde R, Edelman W, Yang K, et al. A targeted chain termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA. 1994;91:8969–8973. doi:10.1073/pnas.91.19.8969
   PubMed Web of Science ®Google Scholar
• Edelmann W, Yang K, Karaguchi M, et al. Tumorigenesis in Mlh1/Apc1638N mutant mice. Cancer Res. 1999;59:1301–1307.
   PubMed Web of Science ®Google Scholar
• Karaguchi M, Edelman W, Yang K, Lipkin M, Kucherlapati R, Brown AM. Tumor-associated Apc mutations in Mlh1-/- Apc 1638N mice reveal a mutational significance of Mlh1 deficiency. Oncogene. 2000;19:5755–5763. doi:10.1038/sj.onc.1203962
   Web of Science ®Google Scholar
• Katdare M, Kopelovich M, Telang N. Efficacy of chemo-preventive agents for growth inhibition of Apc [±] 1638N COL colonic epithelial cells. Int J Mol Med. 2002;10:427–432.
   PubMed Web of Science ®Google Scholar
• Telang N, Li G, Katdare M. Prevention of early-onset familial/hereditary colon cancer: new models and mechanistic biomarkers (Review). Int J Oncol. 2006;28:1523–1529.
   PubMed Web of Science ®Google Scholar
• Telang N. Anti-inflammatory drug resistance selects putative cancer stem cells in a cellular model for genetically predisposed colon cancer. Oncol Letts. 2018;15:642–648.
   Web of Science ®Google Scholar
• Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treatment Reviews. 2006;32(7):491–503. doi:10.1016/j.ctrv.2006.07.001
   PubMed Web of Science ®Google Scholar
• Goldberg RM. Therapy of metastatic colorectal cancer. Oncologist. 2006;11:981–987. doi:10.1634/theoncologist.11-9-981
   PubMed Web of Science ®Google Scholar
• O’Neal BH, Goldberg RM. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. Oncologist. 2008;13:1074–1083. doi:10.1634/theoncologist.2008-0083
   Web of Science ®Google Scholar
• Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21. doi:10.1038/35094017
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Lippman SM. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell. 2004;6:321–326. doi:10.1016/j.ccr.2004.09.021
   Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–726. doi:10.1038/nrc3599
   PubMed Web of Science ®Google Scholar
• Telang N, Katdare M. Combinatorial chemo-prevention of carcinogenic risk in a model for familial colon cancer. Oncol Rep. 2007;17:909–914.
   Web of Science ®Google Scholar
• Telang N, Katdare M. Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome. Oncol Rep. 2009;21:1017–1021. doi:10.3892/or_00000318
   Web of Science ®Google Scholar
• Telang N, Katdare M. Preclinical in vitro models from genetically engineered mice for breast and colon cancer. Oncol Rep. 2011;25:1195–1201. doi:10.3892/or.2011.1215
   Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. doi:10.1038/nrc1590
   PubMed Web of Science ®Google Scholar
• Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Ann Rev Cell Dev Biol. 2007;23:675–699. doi:10.1146/annurev.cellbio.22.010305.104154
   PubMed Web of Science ®Google Scholar
• Patel SA, Ndabahaliye A, Lim PK, Milton R, Rameshwar P. Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer. 2010;2:1–11.
   Google Scholar
• Jiang H, Chen J-F, Pei L, Xie F-W, Liang H-J. Highly enriched CD133 (+) CD44 (+) stem-like cells with CD133(+)CD44High) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis. 2011;28:751–763. doi:10.1007/s10585-011-9407-7
   Web of Science ®Google Scholar
• Wang C, Xie J, Guo J, Manning C, Gore JC, Guo N. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer. Oncol Rep. 2012;28:1301–1308. doi:10.3892/or.2012.1951
   PubMed Web of Science ®Google Scholar
• Zhou J-Y, Chen M, Ma L, Wang X, Chen Y-G, Liu S-L. Role of CD44 (high) /CD133 (high) HCT116 cells in the tumorigenesis of colon cancer. Oncotarget. 2016;7:7657–7666. doi:10.18632/oncotarget.7084
   Google Scholar
• Takahashi K, Tanabe K, Ohnuli M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;1341:861–872. doi:10.1016/j.cell.2007.11.019
   Web of Science ®Google Scholar
• Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141–146. doi:10.1038/nature06534
   PubMed Web of Science ®Google Scholar
• Zhou W, Kallifatidis G, Baumann B, et al. Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 2010;37:551–561. doi:10.3892/ijo_00000704
   PubMed Web of Science ®Google Scholar
• Kallifatidis G, Labsch S, Rausch V, et al. Sulforaphane increase drug-mediated cytotoxicity towards cancer stem-like cells of pancreas and prostate. Mol Cancer Ther. 2011;19:188–195. doi:10.1038/mt.2010.216
   Web of Science ®Google Scholar
• Castro NP, Rangel MC, Merchant AS, MacKinnon G, Cittitta F. Sulforaphane suppresses the growth of triple negative breast cancer stem-like cells in vitro and in vivo. Cancer Prev Res. 2019;12:147–158. doi:10.1158/1940-6207.CAPR-18-0241
   Web of Science ®Google Scholar
• Nguyen PH, Giraud J, Staedel C, et al. All-trans retinoic acid targets gastric cancer stem cells and inhibits patient derived gastric carcinoma tumor growth. Oncogene. 2016;35:5619–5628. doi:10.1038/onc.2016.87
   PubMed Web of Science ®Google Scholar
• Kim SH, Sihgh SV. Role of Kruppel-like factor-4-p21 CIP−1 axis in breast cancer stem-like cell inhibition by benzyl isothio-cyanate. Cancer Prev Res. 2019;12:125–134. doi:10.1158/1940-6207.CAPR-18-0393
   Web of Science ®Google Scholar
• Telang N. Targeting drug-resistant stem cells in a human epidermal growth factor receptror-2-enriched breast cancer model. World Acad Sci J. 2019;1:86–91.
   Google Scholar
• Telang N. Stem cell models for genetically predisposed colon cancer. Oncol Letts. 2020;20:138.
   Web of Science ®Google Scholar